Donald Thornton

2.5k total citations
37 papers, 1.9k citations indexed

About

Donald Thornton is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Donald Thornton has authored 37 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 13 papers in Molecular Biology and 12 papers in Genetics. Recurrent topics in Donald Thornton's work include Cancer Treatment and Pharmacology (10 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Colorectal Cancer Treatments and Studies (5 papers). Donald Thornton is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Colorectal Cancer Treatments and Studies (5 papers). Donald Thornton collaborates with scholars based in United States, Australia and Germany. Donald Thornton's co-authors include Luna Musib, Howard A. Fine, Michael Weller, Lawrence Cher, Wolfgang Wick, Martin J. van den Bent, Astra M. Liepa, Shengyan Hong, Marc C. Chamberlain and Alain Carpentier and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Oncology and Blood.

In The Last Decade

Donald Thornton

36 papers receiving 1.9k citations

Peers

Donald Thornton

ONCOL

GENET

PRM

PFM

Luna Musib United States

Evelyn McKeegan United States

Christine Fritsch Switzerland

Matthew Squires United States

Donna Headlee United States

Christopher A. Slapak United States

R. Osieka Germany

Ben Markman Australia

Sohye Kang United States

Loredana Cleris Italy

Luna Musib United States

Donald Thornton

1.4k ×1.6

952 ×1.4

ONCOL

751 ×1.2

GENET

483 ×1.3

PRM

405 ×1.4

PFM

Citations per year, relative to Donald Thornton Donald Thornton (= 1×) peers Luna Musib

Countries citing papers authored by Donald Thornton

Since Specialization

Citations

This map shows the geographic impact of Donald Thornton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald Thornton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald Thornton more than expected).

Fields of papers citing papers by Donald Thornton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald Thornton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald Thornton. The network helps show where Donald Thornton may publish in the future.

Co-authorship network of co-authors of Donald Thornton

This figure shows the co-authorship network connecting the top 25 collaborators of Donald Thornton. A scholar is included among the top collaborators of Donald Thornton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald Thornton. Donald Thornton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tolaney, Sara M., Nancy U. Lin, Donald Thornton, et al.. (2017). Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer.. Journal of Clinical Oncology. 35(15_suppl). 1019–1019. 41 indexed citations

Michael, Michael, Yung‐Jue Bang, Young Suk Park, et al.. (2017). A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer. Targeted Oncology. 12(4). 463–474. 68 indexed citations

Chiorean, E. Gabriela, Howard S. Höchster, Shivani Nanda, Donald Thornton, & Suzanne Klise. (2017). A phase II study of abemaciclib as a monotherapy and in combination with other agents in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. 35(15_suppl). TPS4150–TPS4150. 5 indexed citations

Cho, Byung-Sik, Zhihong Zeng, Hong Mu, et al.. (2015). Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood. 126(2). 222–232. 95 indexed citations

Tie, Jeanne, Yung‐Jue Bang, Yoon‐Koo Kang, et al.. (2014). Abstract CT215: A phase I trial of LY2874455, a fibroblast growth factor receptor inhibitor, in patients with advanced cance. Cancer Research. 74(19_Supplement). CT215–CT215. 8 indexed citations

Zhang, Zhe, Ting Wang, Jeannette M. Day, et al.. (2012). Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics. Investigational New Drugs. 31(3). 653–660. 16 indexed citations

Schwartzberg, Lee S., Róbert Hermann, Ian W. Flinn, et al.. (2012). Phase II Study of Enzastaurin in Patients with Follicular Lymphoma: Updated Final Clinical Results and Immunohistochemical Correlations. Blood. 120(21). 777–777. 4 indexed citations

Wick, Wolfgang, Vinay K. Puduvalli, Marc C. Chamberlain, et al.. (2010). Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma. Journal of Clinical Oncology. 28(7). 1168–1174. 359 indexed citations

Kreisl, Teri, Svetlana Kotliarova, John A. Butman, et al.. (2010). A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro-Oncology. 12(2). 181–189. 81 indexed citations

10.

Kreisl, Teri, Lyndon Kim, Kraig Moore, et al.. (2009). A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas. Clinical Cancer Research. 15(10). 3617–3623. 40 indexed citations

11.

Camidge, D. Ross, S. Gail Eckhardt, Lia Gore, et al.. (2008). A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors. Anti-Cancer Drugs. 19(1). 77–84. 23 indexed citations

12.

Butowski, Nicholas, Kathleen R. Lamborn, Susan Chang, et al.. (2007). Phase I/pharmacokinetic study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. Molecular Cancer Therapeutics. 6. 1 indexed citations

13.

Li, Shuyu, Michael Lahn, Leslie H. Brail, et al.. (2007). Retrospective analysis of protein kinase C-beta (PKC-β) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas. Biology Direct. 2(1). 8–8. 25 indexed citations

14.

Carducci, Michael A., Luna Musib, Merrill S. Kies, et al.. (2006). Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer. Journal of Clinical Oncology. 24(25). 4092–4099. 150 indexed citations

15.

Eisenberger, Mario A., Menachem Laufer, Nicholas J. Vogelzang, et al.. (2004). Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action. Urology. 63(1). 114–119. 14 indexed citations

16.

John, William J., Joel Picus, Charles D. Blanke, et al.. (2000). Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma. Cancer. 88(8). 1807–1813. 84 indexed citations

17.

Cornwell, David G., et al.. (1998). Cytotoxicity of tocopherols and their quinones in drug‐sensitive and multidrug‐resistant leukemia cells. Lipids. 33(3). 295–301. 46 indexed citations

18.

Triozzi, Pierre L., Chris A. Rhoades, & Donald Thornton. (1995). High-dose chemotherapy for breast cancer. Cancer Treatment Reviews. 21(3). 185–198. 9 indexed citations

19.

Thornton, Donald, et al.. (1995). Antioxidant and cytotoxic tocopheryl quinones in normal and cancer cells. Free Radical Biology and Medicine. 18(6). 963–976. 44 indexed citations

20.

Thornton, Donald, et al.. (1991). Characterization of the 5q‐ breakpoint in an acute nonlymphocytic leukemia patient using pulsed‐field gel electrophoresis. American Journal of Medical Genetics. 41(4). 557–565. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact